000 05940nam a22005175i 4500
999 _c200457120
_d75332
003 DE-He213
005 20231109085748.0
007 cr nn 008mamaa
008 221124s2022 sz | s |||| 0|eng d
020 _a9783031055324
024 7 _a10.1007/978-3-031-05532-4
_2doi
040 _aTR-AnTOB
_beng
_cTR-AnTOB
_erda
060 0 0 _aWP 815
072 7 _aMMF
_2bicssc
072 7 _aMED067000
_2bisacsh
072 7 _aMKF
_2thema
096 _aWP815EBK
245 1 2 _aA Comprehensive Guide to Core Needle Biopsies of the Breast
_h[electronic resource] /
_cedited by Sandra J. Shin, Yunn-Yi Chen, Paula S. Ginter.
250 _a2nd ed. 2022.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2022.
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
505 0 _aEssential Components of a Successful Breast Core Needle Biopsy Program: Imaging Modalities, Sampling Techniques, Specimen Processing, Radiologic/Pathologic Correlation, and Appropriate Follow-Up -- Pattern-Based Evaluation of Breast Core Needle Biopsies -- Multiples in Core Biopsy Samples -- Inflammatory, Reactive, and Infectious Conditions of the Breast -- Adenosis, Sclerosing Lesions, Microglandular Adenosis, and Mucocele-Like Lesions -- Papillary Tumors and Epithelial and Myoepithelial tumors (Pleomorphic adenoma, Adenomyoepithelioma, Malignant Adenomyoepithelioma) -- Fibroepithelial Lesions -- Columnar Cell Lesions -- Intraductal Proliferations (UDH, ADH, DCIS) -- Invasive Ductal Carcinoma, NST (including microinvasive carcinoma), Tubular Carcinoma, and Cribriform Carcinoma -- Triple-Negative/Basal-Like Breast Carcinomas -- Less Common Triple-Negative Breast Cancers and Salivary Gland-Type Tumors (Carcinoma with Apocrine differentiation, Metaplastic carcinoma, Adenoid Cystic Carcinoma, Secretory Carcinoma, Acinic Cell Carcinoma, Mucoepidermoid carcinoma, Tall Cell Carcinoma with Reversed Polarity) -- Special Histologic Types and Special Morphologic Patterns of Invasive Ductal Carcinoma, NST (Mucinous, Micropapillary, Mucinous Cystadenocarcinoma, Cystic Hypersecretory, Glycogen-Rich Clear Cell, Carcinoma with Osteoclast-Like Giant Cells, Neuroendocrine Neoplasms) -- Atypical Lobular Hyperplasia and Lobular Carcinoma In Situ -- Invasive Lobular Carcinoma -- Benign and Malignant Mesenchymal Tumors -- Vascular Lesions of the Breast -- Breast Tumors in Adolescents/Children and Males -- Lesions of the Nippe -- Lymphoid and Hematopoietic Tumors of the Breast -- Special Clinical Settings: Tumors Arising in Pregnancy, Pregnancy-Like (Pseudolactational) Proliferations, Breast Carcinoma in the Pre-neoadjuvant Chemotherapy Setting, Recurrent Breast Carcinoma, and Inflammatory Breast Carcinoma -- Current Standard Clinical Predictive Markers -- Future Role of Molecular Profiling in Small Breast Samples and Personalized Medicine -- Metastases to the Breast -- Dermatologic Mimickers of Breast Lesions Arising in the Breast Skin, Subcutis, or Axilla.
520 _aBreast cancer remains the leading cause of cancer in women, which makes accurate diagnoses on core needle biopsy (CNB) specimens of vital importance in staging and guiding therapy decisions for patients. The first edition of this multi-authored text written by leaders in the field from major academic medical centers provided a comprehensive guide on diagnostic breast pathology in the core biopsy setting. In addition to in-depth coverage of benign and malignant entities encountered in breast core biopsies, the book provided additional resources to improve diagnostic accuracy such as pattern-based approaches to evaluation, mimickers of breast lesions arising in extra-mammary sites, and pitfalls specific to small tissue samples. In recent years, there have been several notable developments in the field of breast pathology including revisions in AJCC breast cancer staging, updated guidelines in the testing and reporting of ER, PR, and HER2, as well as implementation of immunotherapy and companion biomarker testing. In addition, several key updates were included in the most recent edition of the WHO Classification of Breast Tumours (2020). In addition to updates specific to individual breast entities, the second edition provides updates regarding biomarker testing in the primary and metastatic setting, and incorporates newly defined entities and updated definitions of rare tumors in alignment with the WHO Classification of Breast Tumours (2020). Furthermore, this edition addresses the role of CNB in companion biomarker testing for eligibility for immunotherapy in the context of advanced triple-negative breast carcinoma. Written by leaders in the field and edited by expert breast pathologists, The Second Edition of Comprehensive Guide to Core Needle Biopsies of the Breast is the definitive reference on breast core needle biopsies for practicing pathologists, pathology trainees, oncologists and clinicians of patients with breast disease. .
650 0 _aOncology.
650 1 4 _aPathology.
650 2 4 _aOncology.
650 2 4 _aRadiology.
653 0 _aBreast -- Needle biopsy
653 0 _aBreast -- Diseases -- Diagnosis
653 0 _aMedical laboratories
700 1 _aShin, Sandra J.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aChen, Yunn-Yi.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aGinter, Paula S.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
856 4 0 _uhttps://doi.org/10.1007/978-3-031-05532-4
_3Springer eBooks
_zOnline access link to the resource
942 _2NLM
_cEBK
041 _aeng